跳至主要内容
临床试验/NCT04745637
NCT04745637Available不适用

Managed Access Programs for INC424, Ruxolitinib

Novartis Pharmaceuticals0 个研究点开始时间: 2021年2月9日最近更新:
相关药物

试验速览

阶段
不适用
状态
Available

研究概览

简要总结

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

详细描述

CINC424A2405 - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CINC424A2405 to provide access to Ruxolitinib for patients with Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)

CINC424A2001M - No longer available - Ruxolitinib Managed Access Program (MAP) for patients diagnosed with severe/very severe COVID-19 illness

CINC424B2002I - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CINC424B2002I to provide access to Ruxolitinib for patients with Polycythemia Vera (PV)

CINC424C2001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CINC424C2001M to provide access to ruxolitinib for steroid refractory acute and chronic Graft versus Host Disease (SR aGVHD and SR cGHVD).

研究设计

研究类型
Expanded Access

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Industry
责任方
Sponsor

相似试验